Terns Pharmaceuticals, Inc. (TERN) Q3 2023 Earnings Results

Terns Pharmaceutical Misses on EPS, Stock Up 5.34%

Terns Pharmaceutical's earnings report shows a significant miss on EPS, which reflects ongoing challenges in their operations. Despite this, the stock rose by 5.34%, likely driven by investor optimism or other market factors. The lack of revenue data and guidance leaves uncertainty about future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.42	N/A	-37.25%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concerns about ongoing operational hurdles. They remain committed to their long-term goals, indicating a cautious approach moving forward.

Management acknowledged the challenges faced this quarter.

They emphasized a focus on long-term strategy despite current setbacks.

Terns Pharmaceutical Misses on EPS, Stock Up 5.34%

Key numbers

Management commentary

Terns Pharmaceuticals, Inc.

More earnings this week

Terns Pharmaceutical Misses on EPS, Stock Up 5.34%

Key numbers

Management commentary